This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).

开始日期2024-12-01

申办/合作机构

Umoja Biopharma, Inc.初创企业

NCT05312411 / Active, not recruiting临床1期IIT

A Phase I Feasibility and Safety Study of Fluorescein-Specific (FITC-Ew) CAR T Cells in Combination with Parenterally Administered Folate-Fluorescein (UB-TT170) for Osteogenic Sarcoma

The purpose of this study is to see if a new treatment could help patients who have osteosarcoma that does not go away with treatment (is refractory) or comes back after treatment (is recurrent).This study is testing a combination of study therapies, UB-TT170 and genetically modified chimeric antigen receptor T lymphocyte (CAR T) cells, which work together in a way that is different from chemotherapy.
In this study, researchers will take some of your blood and remove the T cells in a process called "apheresis". Then the T cells are taken to a lab and changed to CAR T cells that recognize the flags from UB-TT170. Once researchers think they have grown enough CAR T cells, called antiFL(FITC-E2) CAR T cells, to fight your cancer, you may get some chemotherapy to make room in your body for the new cells and then have those cells put back in your body.
A few days after the you get your CAR T cell infusion you will start to get infusions of UB-TT170, with the dose slowly increasing for the first few infusions until you have reached a maximum dose that you will get on a regular schedule. The UB-TT170 will attach to your tumor cells and flag them so that they attract the CAR T cells. When the CAR T cells see the labeled tumor cells they can kill the tumor cells.
The active part of the study lasts about 8 months, and if you get the CAR T cell infusion you will be in long-term follow-up for 15 years.

开始日期2022-05-20

申办/合作机构

Seattle Children's Hospital

[+1]

100 项与 Umoja Biopharma, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Umoja Biopharma, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Umoja Biopharma, Inc. 相关的文献（医药）

2024-11-01·JOURNAL OF PHARMACEUTICAL SCIENCES

Quality risk management and data integrity in R&D laboratories supporting CMC lifecycle of biological products

Article

作者: Maluf, Karl ; Roach, Shawn ; Hunt, Deanna ; Bowen, Steven ; Cleveland, Chad ; Vessely, Christina ; Christie, Merry ; Kendrick, Brent S ; Rogers, Richard S ; Gabrielson, John P ; Ritter, Nadine

The development of pharmaceutical products is the critical bridge that moves a potential new medicine from academic discovery to applied treatment of patients. It translates an idea for a new drug to bench-level research on how it can be manufactured, formulated, characterized and controlled for use in non-clinical and early clinical trials. From pre-clinical R&D discovery work through the commercial launch, substantial R&D CMC data is generated to develop and optimize cGMP manufacturing and testing operations, while also supporting product comparability, elucidating product / impurity structures, assessing critical quality attributes, developing the drug delivery mode, and developing the product formulation for long-term stability. Significant R&D CMC work continues post-approval to support continuous improvement and market expansion of the commercial product. These activities are crucial elements of Product Lifecycle Management, and taken together, they comprise Pharmaceutical Quality or Chemistry, Manufacturing and Controls (CMC). The objective of this paper is to mitigate the regulatory ambiguity of R&D quality systems with practical, risk-based examples and recommendations when conducting supportive CMC studies for biological products. Making sound strategic CMC decisions under any circumstances assumes data from R&D studies are reliable, traceable, and complete. While there are specific regulatory guidelines on phase-appropriate cGMP activities, none exist for quality practices in R&D CMC laboratories conducting non-cGMP studies. Hindsight is not the time to discover that R&D studies lack key elements that would otherwise have allowed the data to be directly presented to regulators, if needed. There is a strong prospective business interest in protecting considerable investments made for CMC R&D studies. Therefore, establishment of a robust and stage-appropriate R&D laboratory quality system is essential for companies seeking to capitalize on prior knowledge, protect investments, and be prepared for accelerated approval pathways.

2021-12-01·Regulatory toxicology and pharmacology : RTP4区 · 医学

Nonclinical safety assessment of engineered T cell therapies

4区 · 医学

Review

作者: Maier, Curtis C ; Lebrec, Herve ; Shenton, Jacintha ; Ponce, Rafael ; Green, Shon ; Maki, Kazushige

Over the last decade, immunotherapy has established itself as an important novel approach in the treatment of cancer, resulting in a growing importance in oncology. Engineered T cell therapies, namely chimeric antigen receptor (CAR) T cells and T cell receptor (TCR) T cell therapies, are platform technologies that have enabled the development of products with remarkable efficacy in several hematological malignancies and are thus the focus of intense research and development activity. While engineered T cell therapies offer promise in addressing currently intractable cancers, they also present unique challenges, including their nonclinical safety assessment. A workshop organized by HESI and the US Food and Drug Administration (FDA) was held to provide an interdisciplinary forum for representatives of industry, academia and regulatory authorities to share information and debate on current practices for the nonclinical safety evaluation of engineered T cell therapies. This manuscript leverages what was discussed at this workshop to provide an overview of the current important nonclinical safety assessment considerations for the development of these therapeutic modalities (cytokine release syndrome, neurotoxicity, on-target/off-tumor toxicities, off-target effects, gene editing or vector integration-associated genomic injury). The manuscript also discusses approaches used for hazard identification or risk assessment and provides a regulatory perspective on such aspects.

120

项与 Umoja Biopharma, Inc. 相关的新闻（医药）

2024-11-26

·GlobeNewswire-Health Care

Umoja Biopharma to Present at the 7th Annual Evercore ISI HealthCONx Conference

SEATTLE, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf cell therapies that aim to realize the full reach and promise of CAR-T cells, today announced that members of management will participate in a fireside chat and 1x1 investor meetings at the 7th Annual Evercore ISI HealthCONx Conference, which will take place at the Loews Hotel in Coral Gables, Florida, December 3 – 5, 2024. Fireside Chat Date/Time: Thursday, December 5, 2024, 10:25 a.m. ET A live webcast link may be accessed HERE. Meetings: To be scheduled with conference representatives or directly with Umoja About Umoja BiopharmaUmoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR-T cell therapies in both oncology and autoimmunity. Umoja’s VivoVec™ in vivo gene delivery technology empowers a patient’s own immune system to fight disease. Enabling its core technology is the Company’s state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with Umoja on LinkedIn and visit http://umoja-biopharma.com/. InvestorsGrace Kim, Ph.D.Head of Investor Relationsgrace.kim@umoja-biopharma.com MediaMatt WrightReal Chemistrymwright@realchemistry.com

免疫疗法细胞疗法基因疗法

2024-11-21

·GlobeNewswire-Health Care

Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors

SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf therapies that aim to realize the full reach and promise of CAR T-cells, today announced that Scott Myers has been appointed as Chairman of its Board of Directors, succeeding Dieter Weinand who will remain as an advisor. “As Umoja evolves to clinical stage with significant upcoming milestones, I look forward to working with Scott as our Board Chairman,” said Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja. “Scott’s history as both a CEO and chairperson of multiple biotechnology companies in the Pacific Northwest, through significant periods of growth and clinical milestones, will be invaluable as Umoja looks to 2025 and beyond. I would also like to acknowledge and personally thank Dieter for his important contributions to Umoja’s progress over the past two years and am pleased that Dieter has agreed to stay on as strategic advisor for Scott and myself as we continue to build Umoja”. Scott Myers added, “Umoja is uniquely positioned as the leader for in vivo CAR-T cell therapies, with clinical trials recently initiating in multiple geographies and the industry’s first US IND. I am both humbled and excited at the significant opportunity in front of us: to truly transform the way CAR-T cell therapies are delivered so that they may reach their full potential impact on patients.” Mr. Myers currently chairs the boards of directors for Zentalis Pharmaceuticals, Convergent Therapeutics, and Dynavax Technologies. He previously chaired the boards of directors for Ironshore until its acquisition by Collegium Pharmaceuticals and Harpoon Therapeutics until its acquisition by Merck, both in 2024. He was also President and CEO of Viridian Therapeutics, AMAG Pharmaceuticals, Rainier Therapeutics, and Cascadian Therapeutics, and has held additional board and executive leadership roles at other biotechnology and pharmaceutical companies. Mr. Myers holds an MBA in finance from the University of Chicago’s Graduate School of Business (Booth) and a B.A. in Biology from Northwestern University. About Umoja Biopharma Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR-T cell therapies in both oncology and autoimmunity. Umoja’s VivoVec™ in vivo gene delivery technology empowers a patient’s own immune system to fight disease. Enabling its core technology is the Company’s state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with Umoja on LinkedIn and visit http://umoja-biopharma.com/. Investors Grace KimHead of Investor Relationsgrace.kim@umoja-biopharma.com Media Matt Wright Real Chemistrymwright@realchemistry.com

高管变更并购免疫疗法

2024-11-07

·医药魔方Pro

体内CAR-T，风生水起

CAR-T细胞疗法不仅为血癌治疗带来了变革，而且在对抗自身免疫性疾病方面展现出前所未有的潜力。然而，当前的自体CAR-T均是个性化疗法，需要从患者身上收集细胞，然后在实验室中对这些细胞进行改造及培养，最后再将CAR-T细胞重新回输到患者体内，因此面临生产、运输、价格高昂等多重挑战。如何让CAR-T细胞疗法更容易生产、使用更便捷、价格更便宜？以Interius、Umoja、Kelonia为代表的公司正在探索“体内（In vivo）CAR-T疗法”。7月9日，Interius宣布其first-in-class体内CAR-T候选药物INT2104首个I期临床试验已获批。 INT2104以慢病毒载体递送CAR转基因，从而在体内直接生成效应CAR-T细胞和CAR-NK细胞。生成的CAR细胞靶向CD20阳性B细胞以治疗B细胞恶性肿瘤。与体外CAR-T疗法不同，INT2104是一种现货型单剂量治疗方法，通过单次静脉输注全身给药，无需淋巴细胞清除，也不需要任何特殊设备或培训。来源：Interius “体内CAR-T的生成比体外（ex vivo）CAR-T目前的生成过程要快几周，且价格有望大大下降。此外，值得注意的是，接受体外CAR-T细胞疗法治疗的患者需要在细胞疗法输注之前接受严格的化疗方案进行清淋，从而为工程CAR-T细胞腾出空间，但在体内CAR-T生成过程中不能进行清淋，因此患者保持了完整的免疫系统。同时，由于体内CAR-T相比体外CAR-T更少耗竭，因此，它们可能更加活跃，从而带来更好的抗癌效果。”Interius CEO Phil Johnson解释道。体内CAR-T的发展涉及多种多样的载体。Interius、Umoja和Kelonia都采用工程慢病毒载体，这种载体可以永久性地改变免疫细胞。Capstan、Myeloid Therapeutics、Orbital和Orna利用LNP递送RNA以诱导靶细胞中CAR表达的短暂激增。制药巨头们也在布局体内CAR-T疗法，其中，赛诺菲在去年披露该公司有三个体内CAR-T项目处于临床前开发阶段，艾伯维在今年1月宣布与Umoja就开发体内（原位）CAR-T疗法达成潜在总额14.4亿美元的合作，安斯泰来在2月宣布与Kelonia达成合作以开发体内CAR-T…… 整体来看，目前全球已有多个体内CAR-T候选产品已经或即将进入临床。“到2026年，我们将从体内CAR-T陆续公布的试验结果中学到更多东西。” Capstan 的CSO Adrian Bot说道。慢病毒早在体外CAR-T细胞疗法首次进入临床前几年，研究人员就已经在努力重组慢病毒载体，以实现免疫细胞的体内重编程。 Paul-Ehrlich-Institut分子生物技术和基因治疗研究小组负责人Christian Buchholz在20年前就有了早期的灵感。基于2005年发表在Nature Biotechnology杂志上的一项研究（溶瘤病毒麻疹病毒通过引入编码靶向肿瘤特异性CD38、EGFR和EGFRvIII的单链抗体的基因，有效进入肿瘤细胞，实现了定向的抗肿瘤作用），Buchholz想知道一个类似的策略是否可以帮助慢病毒载体进入特定的细胞类型。与期望相符，他在2008年报告称，CD20靶向的慢病毒载体优先被B细胞“吸收”；2012年，其研究又证实，CD8靶向载体能够进入T细胞。但要将慢病毒载体转化为药物，需要强有力的有效载荷。随着杀伤B细胞的CAR-T细胞疗法在2010年首次进入临床，Buchholz看到了机会。2018年，他发表最新成果，研究显示，利用慢病毒载体CD8‐LV（特异性靶向人类CD8细胞）能够直接在体内产生人类 CD19‐CAR T细胞，并导致CD19 B细胞清除。一些biotech开始尝试开发这一策略，并逐渐做出一些调整，包括细胞靶向片段的选择、治疗载荷的选择等。 Interius的团队选择将抗CD7抗体片段嵌入到慢病毒载体中以实现对 CD7阳性T细胞和NK细胞的同时靶向。相比之下，Umoja的策略是使病毒载体有效靶向T细胞的多种不同“信号”，其载体的“早期版本”仅使用了靶向CD3的抗体片段，重编程效率仅在10%-15%之间。通过将CD3抗体片段与CD80和CD58共刺激域融合，研究团队开发的VivoVec 载体能够显著提高重编程效率（达到了50%左右）。 8月24日发表在Blood 杂志上的研究显示，在未进行化疗清淋的情况下，将VivoVec颗粒（VivoVec particles, VVP）注射到非人类灵长类动物体内后，导致了CD20 CAR-T细胞的大量产生，B细胞完全耗尽持续时间超过10周。这些数据支持VivoVec平台的进一步临床开发。来源：Blood 除了表达抗体片段，另一种慢病毒修饰方式是表达“糖蛋白”（如麻疹病毒糖蛋白）。Interius和Umoja使用了来自不同病毒家族的糖蛋白来修饰他们的载体。在CAR设计及选择方面，Interius使用了体外CAR-T细胞疗法所采用的经过验证的、公认有效的CAR结构。Umoja同样为其主导项目选择了经过验证的CAR，但其给慢病毒做了额外的改造，给靶T细胞转导了一个雷帕霉素激活细胞因子受体（rapamycin activated cytokine receptor, RACR）。小分子雷帕霉素可以开启这种人工RACR受体，将IL-15传递给重编程T细胞。“我们已经很好地证明，这不仅延长了这些T细胞的寿命，而且还在小鼠体内产生了更多的工程化CAR。” Umoja公司COO David Fontana说道。不列颠哥伦比亚大学的CAR-T科学家Laura Evgin表示，目前体内CAR-T研究已经获得了一些非常令人信服的临床前数据。值得关注的一点是，慢病毒重编程不需要达到极高的体内转导水平，因为改造后的T细胞会受到抗原刺激的轰击，从而推动它们的扩增。进临床为了获得人体数据，Interius和Umoja两家公司现在正在招募患者进行I期癌症试验。Umoja在7月31日宣布，其原位生成（in-situ generated）CD19 CAR-T细胞疗法UB-VV111 IND申请获得了FDA批准，用于治疗血液恶性肿瘤。该I期研究（NCT06528301）将招募复发/难治性大B细胞淋巴瘤（LBCL）和慢性淋巴细胞白血病（CLL）患者，以评估UB-VV111的安全性、耐受性和临床抗肿瘤活性。不过，在恶性血液肿瘤领域开展体内CAR-T临床研究面临一些挑战，一方面体外CAR-T本身就非常有效，另一方面，如果患者接受体外CAR-T无响应或复发，肿瘤学家可能也不太愿意重复本质上治疗机制相同的策略。 “我们的顾问（执业医师）告诉我们，他们不会让经CD19 CAR-T治疗后复发的患者使用另一种CD19 CAR-T。”Johnson说道。因此，Interius将其先导产品瞄准CD20这一靶点。相关临床试验（NCT06539338）正在招募患者。 Umoja对靶向CD19的体内CAR-T疗法的发展前景更为乐观，但为了绕开“重复”治疗难题，该公司也在推进一种靶向CD22的体内CAR-T。对Buchholz来说，一个关键问题是载体的细胞靶向选择性。“临床中的一个大问题是，这些载体的选择性是否保持了？”他说。这非常关键，“脱靶”将带来安全性问题（包括致癌风险），这也是监管机构会关注的重点。更直接的，研究人员将关注细胞因子释放综合征（CRS）以及免疫细胞相关神经毒性综合征（ICANS）。此外，体内CAR-T的免疫原性也需要考虑，由于体内CAR-T疗法无需且不能清淋，因此保留了患者功能齐全的免疫系统，但这也可能导致对载体的“排斥”。 “我对这些试验的到来感到非常兴奋，但也有一些担忧，我们将拭目以待。”Buchholz说道。除了癌症，体内CAR-T治疗自身免疫性疾病也紧随其后。这一希望来自初步的证据表明体外CAR-T通过杀死B细胞可以诱导免疫重置并可能治愈狼疮。Interius优先推进一款CD19靶向体内CAR–T在2025年开展治疗自身免疫性疾病的临床研究。Umoja及其合作伙伴驯鹿生物（IASO Biotherapeutics）的目标是明年在中国的自身免疫性疾病患者中开始测试一种靶向CD22的候选体内CAR-T。 LNP “上场” 除了慢病毒重编程，基于纳米颗粒载体的体内CAR-T也在发展。2017年，就在Buchholz证明慢病毒载体可以驱动小鼠B细胞耗竭的几个月前，另一个团队报告了基于纳米颗粒载体的类似突破。基于mRNA的COVID-19疫苗的成功随后提高了脂质纳米颗粒（LNP）系统的知名度，包括Capstan和Orbital在内的biotech公司也抓住了体内CAR-T的机会。 2024年3月20日，Capstan完成了 1.75亿美元的 B 轮融资，投资者阵容豪华，强生、BMS、礼来、拜耳、诺华、辉瑞等制药巨头均现身（Capstan自身的创始团队阵容也非常豪华，包括CAR-T先驱Carl H. June、Bruce Levine，mRNA先驱、2023年诺贝尔生理学或医学奖得主Drew Weissman等）。融资所得将用于推进Capstan领先的体内CAR-T候选药物CPTX2309（以LNP递送编码抗CD19 CAR的mRNA到CD8 T细胞中）在自身免疫性疾病中的早期临床概念验证，并进一步开发Capstan基于靶向LNP的管道。对于Capstan的CSO Adrian Bot来说，装载mRNA的LNP的一大优势是它们的可调性。这类疗法只是让T细胞暂时表达B细胞杀伤CAR，因此，剂量调整和重复用药可以最大限度地提高疗效同时最小化长期安全问题。此外，LNP比慢病毒载体更容易生产制造。 “在成本和复杂性方面，相比整个病毒，生产LNP和mRNA要容易得多。”Evgin说道。这位科学家也在与NanoVation合作，利用LNP在体内产生CAR-T。不过，LNP也需要优化以进行体内重编程。用于COVID-19疫苗的LNP载体被设计为反应性载体，以最大化针对其携带的mRNA载荷所编码的病毒抗原的免疫反应。但在用于体内CAR-T开发时，需要降低免疫原性。据悉，Capstan没有采用Teflon型颗粒（具有很强的免疫原性，会在体内长期存在），而是采用了雪花型设计。这种设计的颗粒除非以受体介导的方式迅速被吸收，否则就会分解。为了让这些LNP靶向T细胞，Capstan将一种抗CD8抗体偶联到其载体上，目标是不让CD4 T细胞受到影响。CD8 T细胞负责细胞杀伤，而CD4辅助性T细胞通常会加强炎症活性，而CD4调节性T细胞则会抑制炎症活动。因此，重新编程CD4细胞可能会使治疗效果复杂化，并且可能还会加剧与CAR-T相关的CRS。 Capstan预计将在今年晚些时候披露更多的细节，关于其主要候选药物（CPTX2309）的组成及其在临床前模型中的活性。“这将是我们将这一项目推向临床（首发适应症为自身免疫性疾病）的一个有力跳板。” Bot说。由于基于mRNA的产品不会整合到基因组中，因此不太可能致癌。Evgin表示：“从安全角度，LNP更令人欣慰。” 不过，科学家也提出了一些担心。在血癌中，体外CAR-T在回输到体内后可以存在数年，这些长期存在的细胞可能在抗癌反应的持久性中发挥了作用。那么，基于mRNA的“瞬时”CAR-T在疗效方面会有同样的持久力吗？超越T细胞除T细胞外，科学家们也希望能够将慢病毒和LNP载体用于其它类型细胞的重编程。特别是LNP，已经非常适合于髓细胞重编程。髓细胞完全不需要任何细胞靶向部分就可以“吸收”这些载体。“即使LNP装有T细胞靶向抗体，这类载体的很大一部分通常最终也会进入髓细胞。”Myeloid Therapeutics的CEO Daniel Getts说道。 Myeloid Therapeutics已经有两款体内CAR产品（基于LNP开发的MT-302、MT-303）进入临床，目标是治疗表达TROP2或GPC3的实体肿瘤。 Orna采用了“泛CAR（pan CAR）”策略。该公司表示，他们的主要LNP（不含任何细胞靶向部分）可有效重新编程非人灵长类动物的T细胞、NK细胞和巨噬细胞。该公司已将其优先用于各种血癌和自身免疫适应症。 Carisma及其合作伙伴Moderna优先开发了一种基于LNP的GPC3 CAR巨噬细胞（CAR-M）重编程疗法，目标用于肝癌。此外，上个月,双方共同宣布，他们也将合作开发两款治疗自身免疫性疾病的体内CAR-M疗法。 Carisma CSO Michael Klichinsky表示，尽管目前尚未证实CAR-M疗法的有效性，但实体肿瘤占癌症负担的90%，这里有着真实的未满足临床需求。小结全球范围来看，过去两三年，体内CAR-T研发取得了多项实质性进展。国内方面，目前也已有多家公司布局体内CAR-T，包括济因生物、远泰生物、先博生物(与Orna合作)、博生吉、百替生物、优卡迪等。值得一提的是，2024年10月，济因生物宣布靶向CD19体内CAR-T细胞疗法（慢病毒递送）在研究者发起的临床研究（IIT）中成功治疗一名复发难治急性B淋巴细胞白血病（B-ALL）患者，实现完全缓解（CR），这是首次得到披露的体内CAR-T治疗复发难治B-ALL的临床数据。此外，一例高肿瘤负荷的复发难治弥漫性大B细胞淋巴瘤受试者接受该公司体内CAR-T细胞疗法，亦获得完全缓解（CR）并出院。这些积极结果无疑将进一步增强体内CAR-T赛道参与者的信心。期待技术的突破推动体内CAR-T早日真正获批，造福更多患者。 -上下滑动查看参考资料- [1]https://www.nature.com/articles/d41573-024-00150-z [2]https://www.umoja-biopharma.com/news/abbvie-and-umoja-biopharma-announce-strategic-collaboration-to-develop-novel-in-situ-car-t-cell-therapies/ [3]https://interiusbio.com/2024/07/interius-biotherapeutics-receives-hrec-approval-and-ctn-clearance-from-the-tga-to-commence-a-phase-1-clinical-trial-for-its-first-in-class-in-vivo-car-therapeutic-for-b-cell-malignancies-will-initiate/ [4]https://interiusbio.com/wp-content/uploads/2023/06/Interius-Bio-Data-Poster-June-2023-1.pdf [5]https://www.nature.com/articles/nbt1060 [6]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220327/ [7]https://ashpublications.org/blood/article/144/9/977/516468/In-vivo-CAR-T-cell-generation-in-nonhuman-primates [8]https://www.umoja-biopharma.com/news/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv111-a-cd19-directed-in-situ-car-t-for-hematologic-malignancies/ [9]https://www.capstantx.com/posts/capstan-therapeutics-announces-175m-oversubscribed-series-b-financing/ [10]https://ir.carismatx.com/news-releases/news-release-details/carisma-and-moderna-expand-collaboration-develop-two-vivo-car-m [11]https://mp.weixin.qq.com/s/Cm4hwz6DpItw7faCiXMgNw [12]https://mp.weixin.qq.com/s/KiliqhjYhzssYUBytaLanQ [13]https://mp.weixin.qq.com/s/3Hsscbzz45oiSqOiMDQG9A [14]https://mp.weixin.qq.com/s/rLNhV4Ugu1y4vTYzPhh7GQ [15]https://mp.weixin.qq.com/s/Wi443I8Izx6OF8RyhI2IOA Copyright © 2024 PHARMCUBE. All Rights Reserved. 欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

细胞疗法免疫疗法临床1期基因疗法

100 项与 Umoja Biopharma, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Umoja Biopharma, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

UB-VV111 ( CD19 )	弥漫性大B细胞淋巴瘤更多	临床1期
Fluorescein-Specific CAR T Cells(Umoja Biopharma, Inc.)	骨肉瘤更多	临床1期
UB-VV300 ( CD20 )	自身免疫性疾病更多	临床前
UB-VV410 ( CD22 )	自身免疫性疾病更多	临床前
UB-VV500	多发性骨髓瘤更多	临床前